Amgen Names Elliott M. Levy, M.D., Senior Vice President, Global Development

August 19th, 2014 Amgen (NASDAQ:AMGN) today announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014. Levy comes to Amgen from Bristol-Myers Squibb (BMS), where he most recently served as senior vice president and head, Specialty Development. “Elliott brings a wealth of development and leadership experience to his new role at Amgen,” …

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis

-Second phase three registrational study meets primary and all secondary endpoints -AMG 416 is a novel calcimimetic administered intravenously August 18th, 2014 Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary …

Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates

August 13th, 2014 Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B, …

Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma

April 4, 2014 Amgen today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of …

Amgen’s Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis

Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors Results from Amgen’s Investigational Oncolytic Immunotherapy Presented Today at the Society for Surgical Oncology Congress in Phoenix March 14, 2014 Amgen today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had …